openPR Logo
Press release

Eosinophilic Esophagitis Pipeline 2024 | AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeu

06-19-2024 05:51 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Eosinophilic Esophagitis Pipeline

Eosinophilic Esophagitis Pipeline

DelveInsight's, "Eosinophilic Esophagitis Pipeline Insight 2024" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eosinophilic Esophagitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Eosinophilic Esophagitis Pipeline Report
• DelveInsight's Eosinophilic Esophagitis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Eosinophilic Esophagitis treatment.
• The leading companies working in the Eosinophilic Esophagitis Market include AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeutics, EsoCap, Aqilion, Serpin Pharma, and others.
• Promising Eosinophilic Esophagitis Pipeline Therapies in the various stages of development include Tezepelumab, Etrasimod, Reslizumab, Dupilumab, ESO-101, NDX-3315, and others.
• April 2024:- AstraZeneca- A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING). The study consists of a screening period of 2 to 8 weeks and a 52-week randomized double-blind placebo-controlled treatment period. After completion of the treatment period, participants will be eligible to participate in an optional active treatment extension period (lasting for 24 weeks), followed by a 12-week off-treatment safety follow-up period. Participants who will not participate in the extension period will participate in a 12-week off-treatment safety follow-up period following completion of the 52-week treatment period.
• April 2024:- Ellodi Pharmaceuticals, LP- Fluticasone Propionate Oral Disintegrating Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, Followed by a Single-arm Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis.

Request a sample and discover the recent advances in Eosinophilic Esophagitis Treatment Drugs @ Eosinophilic Esophagitis Pipeline Report- https://www.delveinsight.com/report-store/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Eosinophilic Esophagitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Eosinophilic

Eosinophilic Esophagitis Overview
Eosinophilic esophagitis (EoE) is a chronic disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus. The esophagus is the tube that carries food from the mouth to the stomach. Eosinophils can be found in the esophagus in response to various stimuli or antigen.

Find out more about Eosinophilic Esophagitis Therapeutics Assessment @ Eosinophilic Esophagitis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Eosinophilic Esophagitis Emerging Drugs Profile
• APT-1011: Ellodi Pharmaceuticals.

DelveInsight's Eosinophilic Esophagitis Pipeline Report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Eosinophilic Esophagitis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous

Eosinophilic Esophagitis Pipeline Products have been categorized under various Molecule types such as
• Peptide
• Protein
• Propylene glycols
• Cell Therapy

Eosinophilic Esophagitis Pipeline Therapeutics Assessment
There are approx. 18+ key companies which are developing the Eosinophilic Esophagitis therapies. The Eosinophilic Esophagitis companies which have their Eosinophilic Esophagitis drug candidates in the most advanced stage, i.e. Phase III include, Ellodi Pharmaceuticals.

Learn more about the emerging Eosinophilic Esophagitis Pipeline Therapies @ Eosinophilic Esophagitis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Eosinophilic Esophagitis Pipeline Report
• Coverage- Global
• Eosinophilic Esophagitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Eosinophilic Esophagitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Eosinophilic Esophagitis Companies- AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeutics, EsoCap, Aqilion, Serpin Pharma, and others.
• Eosinophilic Esophagitis Pipeline Therapies- Tezepelumab, Etrasimod, Reslizumab, Dupilumab, ESO-101, NDX-3315, and others.

Dive deep into rich insights for new drugs for Eosinophilic Esophagitis Treatment, Visit @ Eosinophilic Esophagitis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Eosinophilic Esophagitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Eosinophilic Esophagitis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Benralizumab: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IRL201104: Revolo Biotherapeutics
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Mometasone: EsoCap
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. AQ280: Aqilion
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. SP 16: Serpin Pharma
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Eosinophilic Esophagitis Key Companies
24. Eosinophilic Esophagitis Key Products
25. Eosinophilic Esophagitis- Unmet Needs
26. Eosinophilic Esophagitis- Market Drivers and Barriers
27. Eosinophilic Esophagitis- Future Perspectives and Conclusion
28. Eosinophilic Esophagitis Analyst Views
29. Eosinophilic Esophagitis Key Companies
30. Appendix

For further information on the Eosinophilic Esophagitis Pipeline therapeutics, reach out to Eosinophilic Esophagitis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Eosinophilic Esophagitis Pipeline 2024 | AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeu here

News-ID: 3543720 • Views:

More Releases from DelveInsight Business Research LLP

Sepsis Drugs Market Size 2034 | La Jolla Pharmaceuticals, Par Pharmaceutical, Ono Pharmaceutical, Vivacelle Bio, Inotrem, Enlivex Therapeutics, Adrenomed, Shionogi, Asahi Kasei Pharma Corp., AM-Pharma, ABIONYX Pharma, Revimmune, Baxter Healthcare Corporat
Sepsis Drugs Market Size 2034 | La Jolla Pharmaceuticals, Par Pharmaceutical, On …
Sepsis Market Insights, Epidemiology, and Market Forecast-2034" offers a comprehensive understanding of Sepsis, including historical and projected epidemiology. Additionally, the report examines market trends for Sepsis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Key Takeaways from the Sepsis Market Research Report • According to the DelveInsight epidemiology forecast model, in 2022, there were 3,543,995 cases of sepsis recorded in the 7MM, which are expected to
Aplastic Anemia Drugs Market Size 2034 | Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and others
Aplastic Anemia Drugs Market Size 2034 | Pfizer, BioLineRx, Ltd., Regeneron Phar …
DelveInsight's "Aplastic Anemia Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the aplastic anemia, historical and forecasted epidemiology as well as the aplastic anemia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Key Takeaways from the Aplastic Anemia Market Report • The increase in Aplastic Anemia market size is a direct consequence of high incidence in
Nephrotic Syndrome Drugs Market Size 2034 | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharma AB, and others.
Nephrotic Syndrome Drugs Market Size 2034 | GlaxoSmithKline, Goldfinch Bio, Inc. …
DelveInsight's "Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology, and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Key Takeaways from the Nephrotic Syndrome Market Report • The increase in Nephrotic Syndrome Market Size is a direct consequence of expected launch of potential therapies,
Complement 3 Glomerulopathy Drugs Market Size 2034 | ChemoCentryx, Novartis Pharmaceuticals, Omeros Corporation, Apellis Pharmaceuticals, and others.
Complement 3 Glomerulopathy Drugs Market Size 2034 | ChemoCentryx, Novartis Phar …
DelveInsight's "Complement 3 Glomerulopathy Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Complement 3 Glomerulopathy, historical and forecasted epidemiology as well as Complement 3 Glomerulopathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Key Takeaways from the Complement 3 Glomerulopathy Market Report • The total Complement 3 Glomerulopathy diagnosed prevalent population in the 7MM was found

All 5 Releases


More Releases for Eosinophilic

Eosinophilic Asthma Treatment Market Insights, New Project Investment and Potent …
Eosinophilic Asthma Treatment Market research report is a professional and an in-depth study available on the market size, share, growth, trends, in addition to industry evaluation. Eosinophilic Asthma Treatment Market report provides a thorough analysis and competitive analysis by region and added main information like a manufacturing process, raw material and equipment suppliers, various manufacturing associated costs, revenue, historical and futuristic cost, demand and supply data. Moreover, the study presents a
Eosinophilic Esophagitis Drug Market Develop business strategies
MarketResearchReports.Biz adds “Global Eosinophilic Esophagitis Drug Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Eosinophilic Esophagitis Drug and the growth estimates for the forecasted period. Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty,
Eosinophilic Esophagitis Market Share Analysis, by Key Players 2017-2025
Eosinophilic esophagitis is a chronic immunological disorder of the gastrointestinal system, in which a large number of eosinophils (a particular type of white blood cells) are present in the esophagus. The esophagus is a tube that carries food from the mouth to the stomach. Eosinophilic esophagitis is also known as allergic esophagitis. Eosinophils are a part of the body’s immune system. They play a key role in immune regulation and
Eosinophilic Esophagitis Market Key Trends and Forecast Research Report 2025
Eosinophilic esophagitis is a chronic immunological disorder of the gastrointestinal system, in which a large number of eosinophils (a particular type of white blood cells) are present in the esophagus. The esophagus is a tube that carries food from the mouth to the stomach. Eosinophilic esophagitis is also known as allergic esophagitis. Eosinophils are a part of the body’s immune system. They play a key role in immune regulation and
Eosinophilic Asthma Treatment Market Intelligence and Analysis for Period 2017-2 …
Eosinophilic asthma is a form of asthma categorized by greater levels of eosinophils in the air passages. Eosinophilic asthma includes contraction and inflammation of the air passages that makes breathing very difficult. Various symptoms are observed in eosinophilic asthma. The symptoms of eosinophilic asthma can be treated by many asthma medications like bronchodilators, anti-inflammatories and asthma inhaling systems. Eosinophilic asthma treatment includes: Request to Sample of Report- https://www.persistencemarketresearch.com/samples/14077 The allergens can be
Eosinophilic Esophagitis Therapeutic Pipeline Market Review, H2 2017
Summary Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers. GET